When is a preclinical drug worth a mother lode of cash? This top 20 list offers a few answers
When Vertex is intent on a target, the execs are known to splash out big time for experimental products.
That gung-ho spirit was on full display in late 2022 when the biotech handed over $250 million in cash for a preclinical DM1 treatment from Entrada Therapeutics. In their Q1 report, Vertex would go on to say that the Entrada deal was part of $347 million spent on acquired IPR&D charges in the quarter.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.
